Hanhua Liu
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019
Liu, Hanhua; Stiller, Charles A.; Crooks, Colin J.; Rous, Brian; Bythell, Mary; Broggio, John; Rankin, Judith; Nanduri, Vasanta; Lanyon, Peter; Card, Tim R.; Ban, Lu; Elliss-Brookes, Lucy; Broughan, Jennifer M.; Paley, Lizz; Wong, Kwok; Bacon, Andrew; Bishton, Mark; West, Joe
Authors
Charles A. Stiller
Dr COLIN CROOKS Colin.Crooks@nottingham.ac.uk
Clinical Associate Professor
Brian Rous
Mary Bythell
John Broggio
Judith Rankin
Vasanta Nanduri
Peter Lanyon
Dr TIM CARD tim.card@nottingham.ac.uk
Clinical Associate Professor
Lu Ban
Lucy Elliss-Brookes
Jennifer M. Broughan
Lizz Paley
Kwok Wong
ANDREW BACON Andrew.Bacon@nottingham.ac.uk
Professor of Practice
Mark Bishton
JOE WEST JOE.WEST@NOTTINGHAM.AC.UK
Professor of Epidemiology
Abstract
This analysis is the largest population-based study to date to provide contemporary and comprehensive epidemiological estimates of all third edition of the International Classification of Diseases for Oncology (ICD-O-3) coded Langerhans cell histiocytosis (LCH) from England. People of all ages were identified from the National Cancer Registration Dataset using ICD-O-3 morphologies 9751–9754 for neoplasms diagnosed in 2013–2019. A total of 658 patients were identified, of whom 324 (49%) were children aged <15 years. The age-standardised incidence rate was 4.46 (95% confidence interval [CI] 3.99–4.98) per million children and 1.06 (95% CI 0.94–1.18) per million adults aged ≥15 years. Prevalence of LCH was 9.95 (95% CI 9.14–10.81) per million persons at the end of 2019. The 1-year overall survival (OS) was 99% (95% CI 97%–100%) for children and 90% (95% CI 87%–93%) for adults. Those aged ≥60 years had poorer OS than those aged <15 years (hazard ratio [HR] 22.12, 95% CI 7.10–68.94; p < 0.001). People in deprived areas had lower OS than those in the least deprived areas (HR 5.36, 95% CI 1.16–24.87; p=0.03). There will inevitably be other environmental factors and associations yet to be identified, and the continued standardised data collection will allow further evaluation of data over time. This will be increasingly important with developments in LCH management following the large collaborative international trials such as LCH IV.
Citation
Liu, H., Stiller, C. A., Crooks, C. J., Rous, B., Bythell, M., Broggio, J., …West, J. (2022). Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019. British Journal of Haematology, 199(5), 728-738. https://doi.org/10.1111/bjh.18459
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 31, 2022 |
Online Publication Date | Sep 19, 2022 |
Publication Date | 2022-12 |
Deposit Date | Sep 5, 2022 |
Publicly Available Date | Sep 19, 2022 |
Journal | British Journal of Haematology |
Print ISSN | 0007-1048 |
Electronic ISSN | 1365-2141 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 199 |
Issue | 5 |
Pages | 728-738 |
DOI | https://doi.org/10.1111/bjh.18459 |
Keywords | Hematology |
Public URL | https://nottingham-repository.worktribe.com/output/10908615 |
Publisher URL | https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.18459 |
Files
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis
(1.1 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc/4.0/
You might also like
The epidemiology of irritable bowel syndrome
(2014)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search